Pigment Epithelium-derived Factor Maintains Retinal Pigment Epithelium Function by Inhibiting Vascular Endothelial Growth Factor-R2 Signaling through γ-Secretase*

Wet age-related macular degeneration (AMD) attacks the integrity of the retinal pigment epithelium (RPE) barrier system. The pathogenic process was hypothesized to be mediated by vascular endothelial growth factor (VEGF) and antagonized by pigment epithelium-derived factor (PEDF). To dissect these functional interactions, monolayer cultures of RPE cells were established, and changes in transepithelial resistance were evaluated after administration of PEDF, placenta growth factor (VEGF-R1 agonist), and VEGF-E (VEGF-R2 agonist). A recently described mechanism of VEGF inhibition in endothelia required the release of VEGF-R1 intracellular domain by γ-secretase. To evaluate this pathway in the RPE, cells were pretreated with inhibitors DAPT or LY411575. Processing of VEGF receptors was assessed by Western blot analysis. Administration of VEGF-E rapidly increased RPE permeability, and PEDF inhibited the VEGF-E response dose-dependently. Both γ-secretase antagonists prevented the inhibitory effects of PEDF. The co-administration of PEDF and VEGF-E depleted the amount of VEGF-R2 in the membrane and increased the amount of VEGF-R2 ectodomain in the media. Therefore, the inhibitory effect of PEDF appears to be mediated via the processing of VEGF-R2 by γ-secretase. γ-Secretase generates the amyloid-β (Aβ) peptide of Alzheimer disease from its precursor (amyloid precursor protein). This peptide is also a component of drusen in dry AMD. The results support the hypothesis that misregulation of γ-secretase may not only lead to Aβ deposits in dry AMD but can also be damaging to RPE function by blocking the protective effects of PEDF to prevent VEGF from driving the dry to wet AMD transition.

[1]  M. Pangburn,et al.  Oxidative Stress Renders Retinal Pigment Epithelial Cells Susceptible to Complement-mediated Injury* , 2009, The Journal of Biological Chemistry.

[2]  D. Postma,et al.  Expression of ADAMs (“a disintegrin and metalloprotease”) in the human lung , 2009, Virchows Archiv.

[3]  S. Rafii,et al.  VEGF-A Stimulates ADAM17-Dependent Shedding of VEGFR2 and Crosstalk Between VEGFR2 and ERK Signaling , 2008, Circulation research.

[4]  S. Paul,et al.  Geranylgeranyl pyrophosphate stimulates γ‐secretase to increase the generation of Aβ and APP‐CTFγ , 2008 .

[5]  Z. Ablonczy,et al.  VEGF modulation of retinal pigment epithelium resistance. , 2007, Experimental eye research.

[6]  A. Augustin,et al.  TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION: Verteporfin PDT, Bevacizumab, and Dexamethasone , 2007, Retina.

[7]  F. Mascarelli,et al.  Placental growth factor-1 and epithelial haemato–retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy , 2007, Diabetologia.

[8]  Ning Zhang,et al.  Stimulation of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment epithelial cells. , 2006, Molecular vision.

[9]  Raul Heredia,et al.  Identification of a Lipase-linked Cell Membrane Receptor for Pigment Epithelium-derived Factor* , 2006, Journal of Biological Chemistry.

[10]  Arvydas Maminishkis,et al.  Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. , 2006, Investigative ophthalmology & visual science.

[11]  G. Gao,et al.  Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. , 2006, Journal of molecular endocrinology.

[12]  Takafumi Yoshida,et al.  Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. , 2006, Microvascular research.

[13]  J. P. Sy,et al.  Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. , 2006, Ophthalmology.

[14]  W. Jiang,et al.  Pigment Epithelium-derived Factor Inhibits Angiogenesis via Regulated Intracellular Proteolysis of Vascular Endothelial Growth Factor Receptor 1* , 2006, Journal of Biological Chemistry.

[15]  N. Greig,et al.  A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. , 2006, Current Alzheimer research.

[16]  Runsheng Wang,et al.  Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  B. Olsen,et al.  Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. , 2005, The American journal of pathology.

[18]  S. Ichinose,et al.  The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. , 2005, The Journal of clinical investigation.

[19]  J. Tombran-Tink The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. , 2005, Frontiers in bioscience : a journal and virtual library.

[20]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[21]  M. Slomiany,et al.  IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1 alpha expression and activity in retinal pigment epithelial cell line D407. , 2004, Investigative ophthalmology & visual science.

[22]  D. Hicklin,et al.  A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. , 2004, Molecular cancer research : MCR.

[23]  Raphael Kopan,et al.  γ-Secretase: proteasome of the membrane? , 2004, Nature Reviews Molecular Cell Biology.

[24]  B. Kou,et al.  In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. , 2004, Experimental and molecular pathology.

[25]  Alexander J. Rivest,et al.  Characterization of β amyloid assemblies in drusen: The deposits associated with aging and age-related macular degeneration , 2004 .

[26]  D. Darland,et al.  Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. , 2003, Experimental eye research.

[27]  Christoph Dehio,et al.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.

[28]  B. Strooper,et al.  Alzheimer's disease: Mental plaque removal , 2003, Nature.

[29]  A. Milam,et al.  Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. , 2003, Molecular vision.

[30]  A. Schmitz,et al.  Targeting Presenilin-type Aspartic Protease Signal Peptide Peptidase with γ-Secretase Inhibitors* , 2003, The Journal of Biological Chemistry.

[31]  Alexander J. Rivest,et al.  The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Small Is γ-secretase a multienzyme complex for membrane protein degradation? Models and speculations , 2002, Peptides.

[33]  J. Marshall,et al.  Expression of metalloproteinases from human retinal pigment epithelial cells and their effects on the hydraulic conductivity of Bruch's membrane. , 2002, Investigative ophthalmology & visual science.

[34]  I. Morita,et al.  Novel mechanism for age‐related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF , 2001, Journal of cellular physiology.

[35]  T. Golde,et al.  A Novel γ-Secretase Assay Based on Detection of the Putative C-terminal Fragment-γ of Amyloid β Protein Precursor* , 2000, The Journal of Biological Chemistry.

[36]  J. Marshall,et al.  The pathogenesis of edema in diabetic maculopathy. , 1999, Seminars in ophthalmology.

[37]  E. Alberdi,et al.  Binding of Pigment Epithelium-derived Factor (PEDF) to Retinoblastoma Cells and Cerebellar Granule Neurons , 1999, The Journal of Biological Chemistry.

[38]  A Kijlstra,et al.  Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. , 1999, The American journal of pathology.

[39]  D. Bok,et al.  Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[41]  J. Tombran-Tink,et al.  PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. , 1991, Experimental eye research.

[42]  P. Rakoczy,et al.  VEGF differentially regulates transcription and translation of ZO-1α+ and ZO-1α− and mediates trans-epithelial resistance in cultured endothelial and epithelial cells , 2005, Cell and Tissue Research.

[43]  M. Gillies Regulators of vascular permeability: potential sites for intervention in the treatment of macular edema , 2004, Documenta Ophthalmologica.

[44]  Michael F. Marmor,et al.  Mechanisms of fluid accumulation in retinal edema , 2004, Documenta Ophthalmologica.

[45]  Nigel H. Greig,et al.  Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer’s disease , 2002, NeuroMolecular Medicine.